The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The conjunctiva is the membrane lining the outside of the eyeball and the inside of the eyelid. Pink eye is common ... a more serious case that warrants treatment. “These would be indications ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...

The treatment can be used with or ... Common side effects include eye and eyelid inflammation, injection site reactions, and shingles. EBGLYSS is not suitable for individuals allergic to its ...

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Lilly's partner Almirall S.A. has licensed the rights to develop and ...

EBGLYSS provides a new first-line biologic treatment ... include eye and eyelid inflammation, such as redness, swelling and itching; injection site reactions and shingles (herpes zoster).